Cardio Diagnostics Holdings, Inc. (CDIO): Nasdaq/NYSE listing notice — Cardio Diagnostics gets second Nasdaq extension to June 2, 2025 for bid price rule; may reverse split

Cardio Diagnostics Holdings, Inc.

Second Nasdaq letter grants 180-day extension until June 2, 2025, to meet $1.00 minimum bid price.
Common stock (CDIO) and warrants (CDIOW) continue trading; no immediate delisting effect.
Company will consider a reverse stock split, must complete it 10 business days before deadline.
If not compliant by end of extension, Nasdaq will issue delisting notice; company may appeal.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Cardio Diagnostics Holdings, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 4, 2024 (the "Second Nasdaq Bid Price Letter”), Nasdaq notified the Company that Nasdaq’s Staff has determined that the Company is eligible for an additional 180 calendar day period, or until June 2, 2025, to regain compliance (the "Second Compliance Period”). The determination is based on the Company’s meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market with the exception of the Minimum Bid Price Requirement, and the Company’s written notice of its intention to cure t

View on SEC.gov

Browse all listing & compliance notices →

Cardio Diagnostics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001079973-24-001660

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.